Published in final edited form as:

Bioorg Chem. 2007 August ; 35(4): 344–353.

STRUCTURE-BASED DISCOVERY OF A NEW CLASS OF Bcl-x_L ANTAGONISTS

Michele F. Rega^{1,2,3}, Marilisa Leone¹, Dawoon Jung¹, Naomi J.H. Cotton^{1,2}, John L. Stebbins¹, and Maurizio Pellecchia^{1,2,*}

¹Burnham Institute for Medical Research, Cancer Center, 10901 North Torrey Pines Rd, La Jolla, CA 92037

²Burnham Institute for Medical Research, Infectious and Inflammatory Disease Center, 10901 North Torrey Pines Rd, La Jolla, CA 92037

³Department of Pharmaceutical Sciences, University of Salerno, ITALY.

Abstract

Apoptosis, or programmed cell death, plays a key role in normal tissue homeostasis ensuring a proper balance between cell production and cell loss. Anti-apoptotic Bcl-2-family proteins are central regulators of the apoptotic pathway and due to their ability to confer tumor resistance to chemotherapy or radiation, have been recently validated as targets for cancer drug discovery. Since the crucial interaction between pro- and anti-apoptotic members occurs via a conserved region located on the surface of the protein, a viable way to inhibit the anti-death activity of Bcl-2 proteins is to design small molecule inhibitors that occupy this cavity. Here, we describe a structure-based approach that led to the identification of four small molecule inhibitors directed at the hydrophobic groove on the surface of the Bcl-2 family protein Bcl-x_L. The compounds were characterized in a number of assays including in vitro binding using ¹⁵N-labeled protein, a displacement DELFIA assay, and a cell-based viability assay with human cancer cells.

Keywords

Apoptosis; Bcl-2; Bcl-x_L; structure-based; NMR; DELFIA

1. Introduction

Apoptosis represents an efficient mechanism adopted by multicellular organisms in order to eliminate superfluous or damaged cells [1]. Disruption of this mechanism is implicated in several human malignancies [2,3]. Central regulators of the apoptotic pathway are proteins belonging to Bcl-2 (B-cell lymphocyte/leukemia-2) family. Anti-apoptotic Bcl-2 proteins, such as Bcl-x_L, are over-expressed in most human cancer types and therefore are very attractive targets for the development of anticancer agents [4–13]. While Bcl-x_L and its closest relatives such as Bcl-2, Bfl-1, Mcl-1, Bcl-W and Bcl-B, promote cell survival, the structurally similar pro-apoptotic members such as Bak, Bax, Bad, Bim or Bid, promote cell death. The critical mechanism by which pro- and anti-apoptotic members interact, modulating the apoptotic machinery, involves the hydrophobic groove on the surface of the anti-apoptotic members and the BH3 dimerization domain of the pro-apoptotic counterparts [3]. Currently the most

* Send correspondence to mpellecchia@burnham.org Tel.: 858-6463159; FAX: 858-7139925

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

followed approach aimed at designing inhibitors of anti-apoptotic Bcl-2 family proteins is the discovery of small molecules BH3 mimics. We have recently investigated and reported the ability of several natural and semisynthetic compounds [12–14] to antagonize the binding of BH3 peptides to Bcl-2 and Bcl-x_L. Here, we report the design and the exploration of the binding mode of new synthetic compounds targeting Bcl-x_L.

2. Material and methods

2.1. Virtual Docking

Docking studies were performed using the crystal structure of Bcl-x_L in complex with BAK-derived peptide [17], Protein Data Bank code 1BXL. Docking geometries were obtained by using FlexX (five solutions per molecule) implemented on a 32 × 3.2-GHz CPUs Linux cluster. 16,000 compounds were subsequently docked and ranked according to the software FlexX using a modified scoring function as we have recently reported [15]. Top 500 ranking compounds were further investigated to check for H-bonding with Bcl-x_L. Subsequent visual inspection reduced potential candidates with improbable binding geometries from 500 to 320 compounds. The selected 320 compounds (Maybridge) were experimentally tested by NMR. Hit compounds were further tested in additional NMR binding, in vitro displacement and cell-based assays. Comparison between the docked geometries of our hit compounds, Compound 31 (PDB ID 1YSI) and ABT-737 were obtained with SYBYL (TRYPOS, St. Louis). Molecular surfaces were computed with MOLCAD.

2.2. DELFIA (dissociation enhanced lanthanide fluoro-immuno assay)

To each well of 96-wells streptavidin coated plates (Perkin-Elmer), 100 µL of a 10 ng/mL, 4 nM, concentration of biotin-labeled BH3 peptide (Biotin-Ic-G-G-G-Q-V-G-R-Q-L-A-I-I-G-D-DI-N-R; where Ic indicates a hydrocarbon chain of 6 –CH₂– groups) is added. After incubation for 1 h, unbound Biotin-BH3 peptide is eliminated with 3 washing steps. Subsequently, to each well are added 80 µL solution of anti-His Eu-antibody conjugate (100 ng/well; 7.2 µM), 10 µL solution containing a test compound, and 10 µL solution containing His6-Bcl-x_L at concentrations of 150 nM. After 1 h of incubation, each well is washed five times to eliminate unbound protein (and so the Eu-antibody if displaced by the test compound).

The assay buffer from Perkin-Elmer was used in each step. Subsequently, to each well, 200 µL of enhancement solution (Perkin-Elmer) is added, and fluorescence is measured after 30 min incubation (excitation wavelength, 340 nm; emission wavelength, 615 nm). Note that measurements are made in time-resolved mode given the relaxation properties of Eu. Controls include unlabeled peptide, Gossypol and blanks receiving no compounds [16].

2.3. NMR Experiments

NMR-based screening has been conducted by acquiring ¹³C-filtered ¹H, 1D experiments with 500 µL solution of uniformly ¹³C-labeled Bcl-x_L at 50 µM concentration, in absence and presence of added compounds, each at 250 µM concentration. The binding mode has been characterized by recording [¹⁵N, ¹H]-HSQC experiments with 500 µL solution of uniformly ¹⁵N-labeled Bcl-x_L (250 µM concentration) in absence and presence of added compounds, each at 1000 µM concentration. ¹⁵N, ¹³C-labeled and unlabeled Bcl-x_L samples were prepared and purified as described previously [17]. Briefly, *E. coli* strain BL21 was transformed with the pET-21b plasmid (Novagen) carrying the gene coding for Bcl-x_L ΔTM (Bcl-x_L deletion mutant lacking the transmembrane domain). To obtain ¹⁵N and ¹⁵N/¹³C labelled protein, bacteria were grown on M9 minimal media supported with 2 g/L of ¹³C-Glucose and/or 0.5 g/L of ¹⁵NH₄Cl. Induction of protein expression was carried out at OD₆₀₀=0.6 with 1 mM IPTG for 4 hours at 37°C. Following cell harvest and lysis by sonication, the protein was purified using a Ni-affinity column (Amersham). The eluate was extensively

dialyzed against 40 mM phosphate buffer (pH= 7.5) and 150 mM NaCl. Dose–response curve for compound BI-21C5 has been obtained by monitoring the chemical shift of several protein (50 μ M) resonance lines upon titration with the compound. The dissociation constant was obtained by nonlinear fit of the data with PRISM according to the equation $p = \{([To] + [Lo] + Kd) - \sqrt{([To] + [Lo] + Kd)^2 - 4[Lo][To]}\}/2[To]$, where the parameter p represents the fractional population of bound versus free species at equilibrium, which for fast exchanging ligands is measured as $p = (\delta_{obs} - \delta_{free})/(\delta_{sat} - \delta_{free})$, and $[To]$ and $[Lo]$ represent the concentration of target and ligand, respectively [18].

All experiments were performed with a 600 MHz spectrometer Bruker Avance 600 equipped with four rf channels and z -axis pulse-field gradients.

2.4. Cell viability assay

For this assay we used the CellTiter 96[®] AQueous One Solution Cell Proliferation Assay (Promega, Madison, WI). ZR-75-1 cells were grown in RPMI medium supplemented with 10% FBS and 1% penicillin/streptomycin at 37°C and humidified 5% CO₂. Cells were seeded at 5×10^3 /well in a 96-well plate in triplicates. On day 2, compounds were added. On day 4, 20 μ L of MTS reagent was added to 100 μ L of medium. Optical density was then read directly at 490nm using the automated Victor plate reader. Assays were performed in triplicate.

3. Results and discussion

Starting from the 3D structure of Bcl-x_L, by using a molecular docking approach, we have selected a small subset of 320 compounds out of a large library of compounds, for their predicted ability to bind to the BH3 binding pocket of Bcl-x_L. In order to test the ability of these compounds to bind to Bcl-x_L, a ¹³C-labeled sample of the protein was prepared and 1D-¹³C-filtered ¹H-NMR spectra were collected in absence and presence of test compounds. By observing the aliphatic region of the spectra, binding could be readily detected in these simple experiments due to chemical shift changes in active site methyl groups of Ile, Leu, Thr, Val or Ala (region between –0.8 and 0.3 ppm Fig. 1A). While the ¹³C-filter eliminates resonances from solvent and test compounds, the latter rarely display NMR signals in the upfield region of the spectrum. Therefore, a similar screening strategy could be obtained simply by working with unlabeled protein. The advantage of these simple 1D NMR screenings versus more traditional 2D [¹⁵N-¹H] or even [¹³C-¹H]-HSQC experiments is that a relatively low protein concentration (5–50 μ M) could be used to obtain spectra in a reasonably short measurements times (10–40 minutes). Using ¹³C-filtered ¹H, 1D NMR experiments and ¹³C-labeled Bcl-x_L, we have screened the above subset of selected molecules and we found 4 small molecules (Table 1) capable to significantly modify signals coming from amino acids in the active site of our protein. The first quantitative binding data has been achieved for compound BI-21C5, by executing an NMR titration using ¹³C-filtered ¹H, 1D NMR experiments (Fig. 1B). In order to assess whether these compounds were capable of displacing the interactions between Bcl-x_L and its pro-apoptotic counterparts, we have tested them in a heterogeneous Lanthanide-based assay that we have recently developed [16] based on the DELFIA (dissociation enhanced lanthanide fluoro-immuno assay) technology (Perkin-Elmer). In our format, a biotin-labeled BH3 peptide (Biotin-Ic-G-G-G-Q-V-G-R-Q-L-A-I-I-G-D-D-I-N-R) from the protein Bak is bound to streptavidin-coated plates. Then His6-Bcl-x_L and a solution containing Eu-labeled anti-His6 antibody (Perkin-Elmer) are added together with a test inhibitor and then incubated to promote binding. After several washing steps to eliminate unbound Bcl-x_L, an enhancing solution is added to deliver the lanthanide from the antibody to the solution. Residual Eu fluorescence is then detected with an excitation at 340 nm and emission at 615 nm. If the test compound is capable of dissociating Bcl-x_L from the biotinylated-Biotin-BH3 peptide, the antibody carrying the label (Eu) will be washed out and

reduced fluorescence will be detected. A typical binding curve of Biotin-BH3 as a function of the concentration of Bcl-x_L, that gives the dissociation constant for the complex, is reported in Fig. 1C. The k_d value for this peptide in such assay is 11.8 nM as we previously reported [16]. At this point, by using a Bcl-x_L concentration corresponding to the flex point in the latter curve, hit compounds have been tested. A typical displacement curve is reported in Fig. 1D. IC₅₀ values obtained with this method compare very well with displacement values obtained by Fluorescence Polarization Assay [12,19] (Fig. 1 E, F). All compounds displaced the BH3 peptide with IC₅₀ values in the low micromolar range, thus comparably well to most of the currently available Bcl-x_L inhibitors [4–14,20–24]. Once we have established the BH3-displacement activity of our hits, in order to study the binding mode of these compounds to Bcl-x_L we have used [¹⁵N,¹H]-HSQC NMR experiments in the presence and absence of added compounds (Fig. 2A). Based on the available resonance assignments we have also mapped chemical shift changes induced by the compounds into the 3D structure of Bcl-x_L in complex with BAK peptide [17]. This data demonstrates that most of the resonances that are significantly affected by the compound are indeed located in the BH3 binding pocket of Bcl-x_L (Fig. 2B).

When compared with the predicted docked geometries of the compounds, the mapping data also reveal a relatively good agreement (Fig. 3). Interestingly, in agreement with the predicted geometries, the presence of a p-chlorine group in compound BI-21C6 results in rather different chemical shift perturbation map (Fig. 3 C) compared to the parent compound, BI-21C7 (Fig 3 D). These data suggest that there is very good correspondence between the predicted docked geometries of the compounds and the experimental NMR data (Fig. 3).

Recently a potent Bcl-x_L antagonist was derived by using a NMR guided fragment-based approach. Compound 31 [9] and its optimized version, ABT-737 [10] (Fig. 4A, B), bind on the surface of Bcl-x_L occupying two deep and adjacent pockets, as demonstrated by the NMR structure of the complex [9,10] (Fig. 4A). Compared to this bi-dentate compound, our molecules are predicted to occupy only partially either one or the other subpocket (Fig. 4C, D, E, F). For example, compounds BI-21C4, BI-21C5, BI-21C7 all appear to nicely fit into site 2 of the surface of Bcl-x_L. These compounds occupy the space covered by the 3-nitro-4-(2-(phenylthio) ethylamino) benzene-sulfonamide moieties present in Compound 31 [9] and ABT-737 [10] (Fig. 4). Therefore, we could envision the design of novel bi-dentate compounds derivatizing our molecules with bi-aryl fragments that occupy site 1. Conversely compound BI-21C6 appears to bind in site 1 in agreement with chemical shift mapping data despite it differs from compound BI-21C7 by the presence of a chlorine substituent (Table 1, Fig. 4). It is not surprising that a small modification of chemical structure of a compound results in a very different binding mode [25]. The proposed binding mode for BI-21C6 places the chloro-phenyl group in a position that is very similar to what observed in a similar substructure present in Compound 31 [9] and ABT-737 [10]. Therefore, the docked geometries of our compounds, supported by experimental NMR data, and the comparison with ABT-737, provide a framework that may guide the design of compounds with improved affinities.

Finally, to evaluate also the cytotoxic activity of our compounds on human tumors cells, we tested their biological activities using the ZR-75-1 breast cancer cell line, using as positive controls our previously identified Bcl-x_L inhibitors, gossypol [12] and apogossypol [13] (Fig. 5). Interestingly compound BI-21C5 and BI-21C7 exhibit a cell based activity as single agents that is approaching that of apogossypol, suggesting that these molecules represent viable leads for the development of more effective agents.

4. Conclusions

In conclusion, we have discovered a new class of compounds that bind to Bcl-x_L in the BH3 binding pocket, that are able to antagonize the binding of BH3 peptides, and that present cellular

activity. As such, we believe that the scaffolds validated here, together with structural information on their site of binding and binding mode, may represent valuable starting points for further iterative optimizations aimed at the development of novel apoptosis-based therapies.

Acknowledgements

We thank NIH (Grants R03-CA107875 and U19-CA113318), the “California Breast Cancer Research Program” (CBCRP 10WB-0194) and the “Hope for a Cure Foundation” for financial support.

References

1. Vaux DL, Korsmeyer SJ. *Cell* 1999;96:245–254. [PubMed: 9988219]
2. Reed JC. *Current Opinion Oncology* 1995;6:541–546.
3. Johnstone RW, Ruefli AA, Lowe SW. *Cell* 2002;108:153–164. [PubMed: 11832206]
4. Wang JL, Liu D, Zhang ZJ, Shan S, Han X, Srinivasula SM, Croce CM, Alnemri ES, Huang Z. *Proc Natl Acad Sci U S A* 2000;97:7124–7129. [PubMed: 10860979]
5. Degterev A, Lugovskoy A, Cardone M, Mulley B, Wagner G, Mitchison T, Yuan J. *Nat Cell Biol* 2001;3:173–182. [PubMed: 11175750]
6. Tzung SP, Kim KM, Basanez G, Giedt CD, Simon J, Zimmerberg J, Zhang KY, Hockenbery D. *Nat Cell Biol* 2001;3:183–191. [PubMed: 11175751]
7. Enyedy IJ, Ling Y, Nacro K, Tomita Y, Wu X, Cao Y, Guo R, Li B, Zhu X, Huang Y, Long JQ, Roller PP, Yang D, Wang S. *J Med Chem* 2001;44:4313–4324. [PubMed: 11728179]
8. Kaneko M, Nakashima T, Uosaki Y, Hara M, Ikeda S, Kanda Y. *Bioorg Med Chem Lett* 2001;11:887–890. [PubMed: 11294384]
9. Petros AM, Dinges J, Augeri J, Baumeister DSA, Betebenner DA, Bures MG, Elmore SW, Hajduk PJ, Joseph MK, Landis SK, Nettekheim DG, Rosenberg SH, Shen W, Thomas S, Wang X, Zanze I, Zhang H, Fesik SW. *J Med Chem* 2006;49:656–663. [PubMed: 16420051]
10. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettekheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH. *Nature* 2005;435:677–681. [PubMed: 15902208]
11. Wendt MD, Shen W, Kunzer A, McClellan WJ, Bruncko M, Oost TK, Ding H, Joseph MK, Zhang H, Nimmer PM, Ng SC, Shoemaker AR, Petros AM, Oleksijew A, Marsh K, Bauch J, Oltersdorf T, Belli BA, Martineau D, Fesik SW, Rosenberg SH, Elmore SW. *J Med Chem* 2006;49:1165–11681. [PubMed: 16451081]
12. Kitada S, Leone M, Sareth S, Zhai D, Reed JC, Pellecchia M. *J Med Chem* 2003;46:4259–4564. [PubMed: 13678404]
13. Becattini B, Kitada S, Leone M, Monosov E, Chandler S, Zhai D, Kipps TJ, Reed JC, Pellecchia M. *Chem Biol* 2004;11:389–395. [PubMed: 15123268]
14. Pellecchia M, Reed JC. *Curr Pharm Design* 2004;10:1387–1398.
15. Stebbins JL, Jung D, Leone M, Zhang X, Pellecchia M. *J Biol Chem* 2006;281:16643–16648. [PubMed: 16606625]
16. Rega MF, Reed JC, Pellecchia M. *Bioorg Chem*. 2006In press
17. Sattler M, Liang H, Nettekheim D, Meadows RP, Harlan JE, Eberstadt M, Yoon HS, Shuker SB, Chang BS, Minn AJ, Thompson CB, Fesik SW. *Science* 1997;275:983–986. [PubMed: 9020082]
18. Pellecchia M. *Chem Biol* 2005;12:961–971. [PubMed: 16183020]
19. Zhai D, Jin C, Satterthwait AC, Reed JC. *Cell Death and Differentiation* 2006;13:1419–1421. [PubMed: 16645636]
20. Wang JL, Liu D, Zhang ZJ, Shan S, Han X, Srinivasula SM, Croce CM, Alnemri ES, Huang Z. *Proc Natl Acad Sci U S A* 2000;97:7124–7129. [PubMed: 10860979]
21. Leone M, Zhai D, Sareth S, Kitada S, Reed JC, Pellecchia M. *Cancer Res* 2003;63:8118–8121. [PubMed: 14678963]

22. Kutzki O, Park HS, Ernst JT, Orner BP, Yin H, Hamilton AD. *J Am Chem Soc* 2002;124:11838–11839. [PubMed: 12358513]
23. Reed JC, Pellecchia M. *Blood* 2005;106:408–418. [PubMed: 15797997]
24. Wang G, Nikolovska-Coleska Z, Yang CY, Wang R, Tang G, Guo J, Shangary S, Qiu S, Gao W, Yang D, Meagher J, Stuckey J, Krajewski K, Jiang S, Roller PP, Abaan HO, Tomita Y, Wang SJ. *Med Chem* 2006;49:6139–6142.
25. Babaoglu K, Shoichet BK. *Nat Chem Biol* 2006;12:720–723. [PubMed: 17072304]

Figure 1.

In vitro characterization of Bcl-x_L inhibitors. A) Aliphatic region of the ¹³C- filtered 1D ¹H NMR spectrum of Bcl-x_L reported in absence (black) and presence (blue) of a test compound; B) Binding curve for compound BI-21B5 obtained by following the chemical shift changes in the ¹³C- filtered 1D ¹H NMR spectrum of Bcl-x_L upon titration; C) Dose response curve of the binding of Bcl-x_L to a Bak BH3 peptide in the TR-FRET assay; D) Displacement curve for compound BI-21B5 in the TR-FRET assay; E) Displacement curve and chemical structure F) of Gossypol. The IC₅₀ value obtained with the DELFIA is 1.1 μM, which compares well with the value reported by Fluorescence Polarization Assay [12,19].

Figure 2. Chemical shift mapping studies. A) Portions of the $[\text{}^{15}\text{N}, \text{}^1\text{H}]$ -HSQC spectra of Bcl-x_L recorded in absence (black) and in presence of each of the four molecules (in colors). Resonance assignments for amino acid residues that exhibit large shifts are reported; B) Structure of Bcl-x_L in complex with the BH3 peptide from Bak [17] (PDB code 1BXL) showing the chemical shift changes in Bcl-x_L upon ligand binding (blue, large shifts; yellow; no shifts; the Bak peptide is reported in cyan).

Figure 3.

Comparisons between the docked geometries of the compounds and their induced chemical shift perturbations. The docked structure of each compound is reported and the surface of Bcl-x_L (PDB code 1YSI) is colored according to the magnitude of the chemical shift changes in the amide hydrogen and nitrogen nuclei upon ligand binding (red, large shifts; orange, intermediate shifts; yellow, no shifts). Some of the amino acids located in the BH3 binding pocket of Bcl-x_L are also reported. Mapping studies are reported for compounds **BI-21C4**, A); **BI-21C5**, B); **BI-21C6**, C); **BI-21C7**, D).

Figure 4.

Docked and chemical structures of **Compound 31** and **ABT-737** (A, B) and comparison of the docked structures of **BI-21B4** (C), **BI-21B5** (D), **BI-21B6** (E) and **BI21-B7** (F) with **Compound 31** (PDB ID 1YSI). The figures showing the surface of Bcl-x_L were generated by MOLCAD. The color code is according to cavity depth: blue, shallow; yellow, deep.

Figure 5.

Cell viability assays. The effect of two of the newly discovered compounds (**BI-21B5** IC_{50} 11.7 μ M, **BI-21B6** 117.3 μ M) on the viability of the breast cancer ZR-75-1 cell line was assessed by using the MTS assay. The data relative to the known Bcl-x_L antagonists, Gossypol IC_{50} 8.7 μ M and Apogossypol IC_{50} 8.9 μ M, are also reported.

Table 1

Chemical structures, inhibition (DELFA) and binding constants (NMR) relative to the discovered Bcl-x_L antagonists.

CMPD ID	IC ₅₀ μ M
BI-21C4	3.3
BI-21C5	5.1 K _D 19.8 μ M
BI-21C6	0.5
BI-21C7	5.7